Percutaneous Absorption of Pimecrolimus Is Not Increased in Patients with Moderate to Severe Atopic Dermatitis when Pimecrolimus Cream 1% Is Applied under Occlusion

Percutaneous absorption of potent topical corticosteroids in patients with severe atopic dermatitis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2009.12.048 ◽

2010 ◽

Vol 63 (5) ◽

pp. 911-913 ◽

Cited By ~ 10

Author(s):

Sara G.A. van Velsen ◽

Inge M. Haeck ◽

Carla A.F.M. Bruijnzeel-Koomen

Keyword(s):

Atopic Dermatitis ◽

Percutaneous Absorption ◽

Topical Corticosteroids

Immunodeficiencies in severe atopic dermatitis. Depressed chemotaxis and lymphocyte transformation

Archives of Dermatology ◽

10.1001/archderm.112.10.1391 ◽

1976 ◽

Vol 112 (10) ◽

pp. 1391-1396 ◽

Cited By ~ 40

Author(s):

J. L. Rogge

Keyword(s):

Atopic Dermatitis ◽

Lymphocyte Transformation ◽

Elevated RANTES Levels in Plasma or Skin and Decreased Plasma IL-10 Levels in Subsets of Patients With Severe Atopic Dermatitis

Archives of Dermatology ◽

10.1001/archderm.136.1.125 ◽

2000 ◽

Vol 136 (1) ◽

pp. 125-126 ◽

Cited By ~ 24

Author(s):

Y. Niwa

Keyword(s):

Atopic Dermatitis ◽

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Case Medical Research ◽

10.31525/ct1-nct03989349 ◽

2019 ◽

Author(s):

Keyword(s):

Atopic Dermatitis ◽

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

Case Medical Research ◽

10.31525/ct1-nct04162769 ◽

2019 ◽

Author(s):

Keyword(s):

Atopic Dermatitis ◽

Safety And Efficacy

Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis

Case Medical Research ◽

10.31525/ct1-nct04178967 ◽

2019 ◽

Author(s):

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety

Faculty Opinions recommendation of Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718101782.793483405 ◽

2013 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Atopic Dermatitis ◽

Combined Therapy ◽

New Approach

Faculty Opinions recommendation of Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718485867.793499544 ◽

2014 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Atopic Dermatitis ◽

Faculty Opinions recommendation of Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725267890.793505964 ◽

2015 ◽

Author(s):

Ramsay Fuleihan ◽

Whitney Stevens

Keyword(s):

Atopic Dermatitis ◽

Molecular Signature ◽

Faculty Opinions recommendation of Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732534768.793555539 ◽

2019 ◽

Author(s):

Carsten Flohr

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Efficacy And Safety ◽

Double Blind